<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>BOSULIF- bosutinib monohydrate tablet, film coated </strong><br>Pfizer Laboratories Div Pfizer Inc<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use BOSULIF safely and effectively. See full prescribing information for BOSULIF. <br><br>BOSULIF<span class="Sup">®</span> (bosutinib) tablets, for oral use <br>Initial U.S. Approval: 2012</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table class="Noautorules" width="100%">
<col align="left" valign="bottom" width="90%">
<col align="right" valign="bottom" width="10%">
<tbody class="Headless">
<tr>
<td align="left">Dosage and Administration, Recommended Starting Dosage with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> (<a href="#S2.7">2.7</a>)</td>
<td align="right">11/2014</td>
</tr>
<tr>
<td align="left">Warnings and Precautions, Renal Toxicity (<a href="#S5.5">5.5</a>)</td>
<td align="right">11/2014</td>
</tr>
</tbody>
</table></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">BOSULIF is a kinase inhibitor indicated for the treatment of adult patients with chronic, accelerated, or blast phase Ph+ <span class="product-label-link" type="condition" conceptid="134603" conceptname="Chronic myeloid leukemia">chronic myelogenous leukemia</span> (CML) with resistance or intolerance to prior therapy. (<a href="#S1">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Recommended Dose: 500 mg orally once daily with food. (<a href="#S2.1">2.1</a>)</li>
<li>Consider dose escalation to 600 mg daily in patients who do not reach complete hematologic response by week 8 or complete cytogenetic response by week 12 and do not have Grade 3 or greater adverse reactions. (<a href="#S2.2">2.2</a>)</li>
<li>Adjust dosage for hematologic and non-hematologic toxicity. (<a href="#S2.3">2.3</a>, <a href="#S2.4">2.4</a>)</li>
<li>Adjust dosage for hepatic and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. (<a href="#S2.7">2.7</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets: 100 mg and 500 mg. (<a href="#S3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to BOSULIF. (<a href="#S4">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="197596" conceptname="Toxic gastroenteritis">Gastrointestinal Toxicity</span>: Monitor and manage as necessary. Withhold, dose reduce, or discontinue BOSULIF. (<a href="#S2.3">2.3</a>, <a href="#S5.1">5.1</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span>: Monitor blood counts and manage as necessary. (<a href="#S2.4">2.4</a>, <a href="#S5.2">5.2</a>)</li>
<li>Hepatic Toxicity: Monitor liver enzymes at least monthly for the first three months and as needed. Withhold, dose reduce, or discontinue BOSULIF. (<a href="#S2.3">2.3</a>, <a href="#S5.3">5.3</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span>: Monitor patients and manage using standard of care treatment. Withhold, dose reduce, or discontinue BOSULIF. (<a href="#S2.3">2.3</a>, <a href="#S5.4">5.4</a>)</li>
<li>Renal Toxicity Monitor patients for renal function at baseline and during therapy with BOSULIF (<a href="#S5.5">5.5</a>)</li>
<li>Embryofetal Toxicity: May cause fetal harm. Females of reproductive potential should avoid becoming pregnant while being treated with BOSULIF. (<a href="#S5.6">5.6</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (incidence greater than 20%) are <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>. (<a href="#S6">6</a>) </p>
<br><p class="Highlighta">To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or <span class="Bold"><span class="Italics">www.fda.gov/medwatch</span>.</span> </p>
</div>
<div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>CYP3A Inhibitors and Inducers: Avoid concurrent use of BOSULIF with strong or moderate CYP3A inhibitors and inducers. (<a href="#S2.5">2.5</a>, <a href="#S2.6">2.6</a>, <a href="#S7.1">7.1</a>, <a href="#S7.2">7.2</a>)</li>
<li>Proton Pump Inhibitors: May decrease bosutinib drug levels. Consider short-acting antacids in place of proton pump inhibitors. (<a href="#S7.2">7.2</a>)</li>
</ul></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
</div>
<div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
</div>
<div><div></div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 11/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Recommended Dosing </a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Dose Escalation </a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Dose Adjustments for Non-Hematologic Adverse Reactions</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Dose Adjustments for <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span></a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Concomitant Use With CYP3A Inhibitors</a></h2>
<h2><a href="#section-2.6" class="toc">2.6 Concomitant Use With CYP3A Inducers</a></h2>
<h2><a href="#section-2.7" class="toc">2.7 Recommended Starting Dosage with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="197596" conceptname="Toxic gastroenteritis">Gastrointestinal Toxicity</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Hepatic Toxicity </a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Renal Toxicity</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Embryofetal Toxicity</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Drugs That May Increase Bosutinib Plasma Concentrations</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Drugs That May Decrease Bosutinib Plasma Concentrations</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Drugs That May Have Their Plasma Concentrations Altered By Bosutinib</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> </a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-14.1" class="toc">16.1 How Supplied</a></h2>
<h2><a href="#section-14.2" class="toc">16.2 Storage</a></h2>
<h2><a href="#section-14.3" class="toc">16.3 Handling and Disposal</a></h2>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">BOSULIF is indicated for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) <span class="product-label-link" type="condition" conceptid="134603" conceptname="Chronic myeloid leukemia">chronic myelogenous leukemia</span> (CML) with resistance or intolerance to prior therapy.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Recommended Dosing </h2>
<p class="First">The recommended dose and schedule of BOSULIF is 500 mg orally once daily with food. Continue treatment with BOSULIF until disease progression or patient intolerance. </p>
<p>If a dose is missed beyond 12 hours, the patient should skip the dose and take the usual prescribed dose on the following day.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Dose Escalation </h2>
<p class="First">Consider dose escalation to 600 mg once daily with food in patients who do not reach complete hematological response (CHR) by week 8 or a complete cytogenetic response (CCyR) by week 12, who did not have Grade 3 or higher adverse reactions, and who are currently taking 500 mg daily. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Dose Adjustments for Non-Hematologic Adverse Reactions</h2>
<p class="First">Elevated liver transaminases: If elevations in liver transaminases greater than 5×institutional upper limit of normal (ULN) occur, withhold BOSULIF until recovery to less than or equal to 2.5×ULN and resume at 400 mg once daily thereafter. If recovery takes longer than 4 weeks, discontinue BOSULIF. If transaminase elevations greater than or equal to 3×ULN occur concurrently with bilirubin elevations greater than 2×ULN and alkaline phosphatase less than 2×ULN (Hy's law case definition), discontinue BOSULIF <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>: For NCI CTCAE Grade 3–4 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (increase of greater than or equal to 7 stools/day over baseline/pretreatment), withhold BOSULIF until recovery to Grade less than or equal to 1. BOSULIF may be resumed at 400 mg once daily <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</p>
<p>For other clinically significant, moderate or severe non-hematological toxicity, withhold BOSULIF until the toxicity has resolved, then consider resuming BOSULIF at 400 mg once daily. If clinically appropriate, consider re-escalating the dose of BOSULIF to 500 mg once daily. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.4"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Dose Adjustments for <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span></h2>
<p class="First">Dose reductions for severe or persistent <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> are described below (Table 1). </p>
<a name="table1"></a><table width="90%">
<caption><span>Table 1: Dose Adjustments for <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></span></caption>
<col align="left" valign="middle" width="30%">
<col align="left" valign="middle" width="70%">
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Absolute Neutrophil Count</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule" align="left" valign="top">ANC<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> less than 1000×10<span class="Sup">6</span>/L</td>
<td class="Rrule" align="left">Withhold BOSULIF until ANC greater than or equal to1000×10<span class="Sup">6</span>/L <span class="Underline">and</span> platelets greater than or equal to 50,000×10<span class="Sup">6</span>/L.</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">or</td>
<td class="Rrule" align="left"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Platelets less than 50,000×10<span class="Sup">6</span>/L</td>
<td class="Rrule" align="left">Resume treatment with BOSULIF at the same dose if recovery occurs within 2 weeks. If blood counts remain low for greater than 2 weeks, upon recovery, reduce dose by 100 mg and resume treatment.</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"></td>
<td class="Rrule" align="left">
<br>If <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">cytopenia</span> recurs, reduce dose by an additional 100 mg upon recovery and resume treatment<span class="Italics">.</span>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"></td>
<td class="Rrule" align="left">
<br>Doses less than 300 mg/day have not been evaluated.</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.5"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Concomitant Use With CYP3A Inhibitors</h2>
<p class="First">Avoid the concomitant use of strong or moderate CYP3A and/or P-gp inhibitors with BOSULIF as an increase in bosutinib plasma concentration is expected (strong CYP3A inhibitors include ritonavir, indinavir, nelfinavir, saquinavir, ketoconazole, boceprevir, telaprevir, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, nefazodone and conivaptan. Moderate CYP3A inhibitors include fluconazole, darunavir, erythromycin, diltiazem, atazanavir, aprepitant, amprenavir, fosamprevir, crizotinib, imatinib, verapamil, grapefruit products and ciprofloxacin) <span class="Italics">[see <a href="#S7.1">Drug Interactions (7.1)</a>]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.6"></a><a name="section-2.6"></a><p></p>
<h2>2.6 Concomitant Use With CYP3A Inducers</h2>
<p class="First">Avoid the concomitant use of strong or moderate CYP3A inducers with BOSULIF as a large reduction in exposure is expected (strong CYP3A inducers include rifampin, phenytoin, carbamazepine, St. John's Wort, rifabutin and phenobarbital. Moderate CYP3A inducers include bosentan, nafcillin, efavirenz, modafinil and etravirine) <span class="Italics">[see <a href="#S7.2">Drug Interactions (7.2)</a>]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.7"></a><a name="section-2.7"></a><p></p>
<h2>2.7 Recommended Starting Dosage with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<table width="90%">
<col align="left" valign="middle" width="60%">
<col align="left" valign="middle" width="40%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center"><span class="XmChange">Organ Function Status</span></th>
<th class="Rrule" align="center">Recommended Starting Dosage</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="XmChange">Normal hepatic and renal function</span></td>
<td class="Rrule" align="left">500 mg once daily</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="2"><span class="XmChange"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic impairment</span></span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="XmChange">  Mild (Child-Pugh A), Moderate (Child-Pugh B) or severe (Child-Pugh C)</span></td>
<td class="Rrule" align="left">200 mg daily</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="2"><span class="XmChange"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span></span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="XmChange">  Creatinine clearance 30 to 50 mL/min</span></td>
<td class="Rrule" align="left">400 mg daily</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="XmChange">  Creatinine clearance less than 30 mL/min</span></td>
<td class="Rrule" align="left">300 mg daily</td>
</tr>
<tr class="Last"><td class="Lrule Rrule" align="left" colspan="2"><span class="XmChange"><span class="Italics">[see <a href="#S8.6">Use in Specific Populations (8.6</a>,<a href="#S8.7">8.7</a>) and <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</span></td></tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">100 mg tablets: yellow, oval, biconvex, film-coated tablets debossed with "Pfizer" on one side and "100" on the other. </p>
<p>500 mg tablets: red, oval, biconvex, film-coated tablets debossed with "Pfizer" on one side and "500" on the other. </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to BOSULIF. In the BOSULIF clinical trials, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span> occurred in less than 0.2% of treated patients.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="197596" conceptname="Toxic gastroenteritis">Gastrointestinal Toxicity</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> occur with BOSULIF treatment. Monitor and manage patients using standards of care, including antidiarrheals, antiemetics, and fluid replacement. In the single-arm Phase 1/2 clinical trial, the median time to onset for <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (all grades) was 2 days and the median duration per event was 1 day. Among the patients who experienced <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, the median number of episodes of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> per patient during treatment with BOSULIF was 3 (range 1–221). To manage <span class="product-label-link" type="condition" conceptid="197596" conceptname="Toxic gastroenteritis">gastrointestinal toxicity</span>, withhold, dose reduce, or discontinue BOSULIF as necessary <span class="Italics">[see <a href="#S2.3">Dosage and Administration (2.3)</a> and <a href="#S6">Adverse Reactions (6)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> and <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> occur with BOSULIF treatment. Perform complete blood counts weekly for the first month of therapy and then monthly thereafter, or as clinically indicated. To manage <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>, withhold, dose reduce, or discontinue BOSULIF as necessary <span class="Italics">[see <a href="#S2.4">Dosage and Administration (2.4)</a> and <a href="#S6">Adverse Reactions (6)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Hepatic Toxicity </h2>
<p class="First">One case consistent with drug induced <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> (defined as concurrent elevations in ALT or AST greater than or equal to 3×ULN with total bilirubin greater than 2×ULN and alkaline phosphatase less than 2×ULN) occurred in a trial of BOSULIF in combination with letrozole. The patient recovered fully following discontinuation of BOSULIF. This case represented 1 out of 1209 patients in BOSULIF clinical trials. </p>
<p>In the 546 patients from the safety population, the incidence of ALT elevation was 17% and AST elevation was 14%. Twenty percent of the patients experienced an increase in either ALT or AST. Most cases of transaminase elevations occurred early in treatment; of patients who experienced transaminase elevations of any grade, more than 80% experienced their first event within the first 3 months. The median time to onset of increased ALT and AST was 30 and 33 days, respectively, and the median duration for each was 21 days.</p>
<p>Perform hepatic enzyme tests monthly for the first three months of BOSULIF treatment and as clinically indicated. In patients with transaminase elevations, monitor liver enzymes more frequently. Withhold, dose reduce, or discontinue BOSULIF as necessary <span class="Italics">[see <a href="#S2.3">Dosage and Administration (2.3)</a> and <a href="#S6">Adverse Reactions (6)</a>]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> occurs with BOSULIF and may manifest as <span class="product-label-link" type="condition" conceptid="4161701" conceptname="Pericardial effusion">pericardial effusion</span>, <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, and/or <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>.</p>
<p>In the single-arm Phase 1/2 clinical trial in 546 patients with CML treated with prior therapy, severe <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> was reported in 14 patients (3%). Specifically, 9 patients had a Grade 3 or 4 <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>, 3 patients experienced both Grade 3 or Grade 4 pleural and <span class="product-label-link" type="condition" conceptid="4161701" conceptname="Pericardial effusion">pericardial effusions</span>, 1 patient experienced Grade 3 peripheral and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, and 1 patient had a Grade 3 <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. </p>
<p>Monitor and manage patients using standards of care. Interrupt, dose reduce or discontinue BOSULIF as necessary <span class="Italics">[see <a href="#S2.3">Dosage and Administration (2.3)</a> and <a href="#S6">Adverse Reactions (6)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Renal Toxicity</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">An on-treatment decline in estimated glomerular filtration rate (eGFR) has occurred in patients treated with BOSULIF. Table 2 identifies the shift from baseline to lowest observed estimated glomerular filtration rate (eGFR) during BOSULIF therapy for patients in the global Ph+ <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">Leukemia</span> studies. The median duration of therapy with BOSULIF was approximately 17 months (range, 0.03 to 95) for patients in these studies.</span></p>
<a name="table2"></a><table width="100%">
<caption><span>Table 2: Shift from Baseline to Lowest Observed eGFR Group During Treatment Safety Population in Clinical Studies (n=818)<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a></span></caption>
<col align="left" valign="bottom" width="20%">
<col align="center" valign="bottom" width="10%">
<col align="center" valign="bottom" width="10%">
<col align="center" valign="bottom" width="10%">
<col align="center" valign="bottom" width="12%">
<col align="center" valign="bottom" width="13%">
<col align="center" valign="bottom" width="10%">
<col align="center" valign="bottom" width="15%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center" colspan="2"><span class="XmChange">Baseline</span></th>
<th class="Rrule" align="center" colspan="6">Follow Up</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="center"><span class="XmChange">Renal Function Status</span></th>
<th class="Rrule" align="center">n</th>
<th class="Rrule" align="center">Normal <br>n (%)</th>
<th class="Rrule" align="center">Mild<br>n (%)</th>
<th class="Rrule" align="center">Mild to Moderate<br>n (%)</th>
<th class="Rrule" align="center">Moderate to Severe <br>n (%)</th>
<th class="Rrule" align="center">Severe<br>n (%)</th>
<th class="Rrule" align="center"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Kidney Failure</span><br>n (%)</th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="8">Notes: Grading is based on Modification in Diet in <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span> method (MDRD).<br>KDIGO Classification by eGFR: Normal: greater than or equal to 90, Mild: 60 to less than 90, Mild to Moderate: 45 to less than 60, Moderate to Severe: 30 to less than 45, Severe: 15 to less than 30, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Kidney Failure</span>: less than 15 ml/min/1.73 m<span class="Sup">2</span>.  </td></tr>
<tr><td colspan="8" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Among the 818 patients, eGFR was missing in 5 patients at baseline or on-therapy. There were no patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span> at baseline.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="XmChange">Normal</span></td>
<td class="Rrule" align="center">274</td>
<td class="Rrule" align="center">53 (19)</td>
<td class="Rrule" align="center">174 (64)</td>
<td class="Rrule" align="center">30 (11)</td>
<td class="Rrule" align="center">14 (5)</td>
<td class="Rrule" align="center">1 (&lt;1)</td>
<td class="Rrule" align="center">1 (&lt;1)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Mild </td>
<td class="Rrule" align="center">438</td>
<td class="Rrule" align="center">10 (2)</td>
<td class="Rrule" align="center">170 (39)</td>
<td class="Rrule" align="center">177 (40)</td>
<td class="Rrule" align="center">63 (14)</td>
<td class="Rrule" align="center">14 (3)</td>
<td class="Rrule" align="center">2 (1)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Mild to Moderate </td>
<td class="Rrule" align="center">79</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">4 (5)</td>
<td class="Rrule" align="center">28 (35)</td>
<td class="Rrule" align="center">37 (47)</td>
<td class="Rrule" align="center">10 (13)</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Moderate to Severe </td>
<td class="Rrule" align="center">24</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">1 (4)</td>
<td class="Rrule" align="center">1 (4)</td>
<td class="Rrule" align="center">6 (25)</td>
<td class="Rrule" align="center">15 (63)</td>
<td class="Rrule" align="center">1 (4)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Severe </td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">1 (100)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Total</td>
<td class="Rrule" align="center">816</td>
<td class="Rrule" align="center">63 (8)</td>
<td class="Rrule" align="center">349 (43)</td>
<td class="Rrule" align="center">236 (29)</td>
<td class="Rrule" align="center">120 (15)</td>
<td class="Rrule" align="center">40 (5)</td>
<td class="Rrule" align="center">5 (1)</td>
</tr>
</tbody>
</table>
<p style="border-left:1px solid;"><span class="XmChange">Monitor renal function at baseline and during therapy with BOSULIF, with particular attention to those patients who have preexisting <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or risk factors for renal dysfunction. Consider dose adjustment in patients with baseline and treatment emergent <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see <a href="#S2.7">Dosage and Administration (2.7)</a>].</span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Embryofetal Toxicity</h2>
<p class="First">There are no adequate and well controlled studies of BOSULIF in pregnant women. BOSULIF can cause fetal harm when administered to a pregnant woman. Bosutinib caused embryofetal toxicities in rabbits at maternal exposures that were greater than the clinical exposure at the recommended bosutinib dose of 500 mg/day. Females of reproductive potential should be advised to avoid pregnancy while being treated with BOSULIF. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus <span class="Italics">[see <a href="#S8.1">Use in Specific Populations (8.1)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are discussed in greater detail in other sections of the labeling:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="197596" conceptname="Toxic gastroenteritis">Gastrointestinal toxicity</span> <span class="Italics">[see <a href="#S2.3">Dosage and Administration (2.3)</a> and <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</li>
<li><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span> <span class="Italics">[see <a href="#S2.4">Dosage and Administration (2.4)</a> and <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>.</li>
<li>Hepatic toxicity <span class="Italics">[see <a href="#S2.5">Dosage and Administration (2.5)</a> and <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>. </li>
<li><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> <span class="Italics">[see <a href="#S5.4">Warnings and Precautions (5.4)</a>]</span>.</li>
<li>Renal toxicity <span class="Italics">[see <a href="#S5.5">Warnings and Precautions (5.5)</a>]</span>.</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. </p>
<p>Serious adverse reactions reported include <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span> <span class="Italics">[see <a href="#S4">Contraindications (4)</a>]</span>, <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>, <span class="product-label-link" type="condition" conceptid="197596" conceptname="Toxic gastroenteritis">gastrointestinal toxicity</span> (<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>), <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, hepatotoxicity and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</p>
<p>Adverse reactions of any toxicity grade reported for greater than 20% of patients in the Phase 1/2 safety population (n=546) were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (82%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (46%), <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (41%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (39%), <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (37%), <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (35%), <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (27%), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> (26%), and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (24%) <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a>]</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Underline">Adverse Reactions in Patients with Imatinib-Resistant or -Intolerant Ph+ Chronic Phase (CP), Accelerated Phase (AP), and Blast Phase (BP) CML</span></p>
<p>The single-arm Phase 1/2 clinical trial (Study 1) enrolled patients with Ph+ chronic, accelerated, or blast phase <span class="product-label-link" type="condition" conceptid="134603" conceptname="Chronic myeloid leukemia">chronic myelogenous leukemia</span> (CML) and with resistance or intolerance to prior therapy <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a>]</span>. The safety population (received at least 1 dose of BOSULIF) included 546 CML patients:</p>
<ul>
<li>287 patients with CP CML previously treated with imatinib only who had a median duration of BOSULIF treatment of 24 months, and a median dose intensity of 484 mg/day. </li>
<li>119 patients with CP CML previously treated with both imatinib and at least 1 additional TKI who had a median duration of BOSULIF treatment of 9 months and a median dose intensity of 475 mg/day. </li>
<li>140 patients with advanced phase CML including 76 patients with AP CML and 64 patients with BP CML. In the patients with AP CML and BP CML, the median duration of BOSULIF treatment was 10 months and 3 months, respectively. The median dose intensity was 483 mg/day, and 500 mg/day, in the AP CML and BP CML cohorts, respectively. </li>
</ul>
<p>	Table 3 identifies adverse reactions greater than or equal to 10% for all grades and grades 3 or 4 for the Phase 1/2 CML safety population. </p>
<a name="table3"></a><table width="75%">
<caption><span>Table 3: Adverse Reactions (10% or Greater) in Patients with CML in Study 1</span></caption>
<col align="left" valign="top" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center" colspan="2">Chronic Phase CML<br>N=406</th>
<th class="Rrule" align="center" colspan="2">Advanced Phase CML<br>N=140</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule Toprule" align="center">All Grades <br>(%)</th>
<th class="Rrule Toprule" align="center">Grade 3/4<br>(%)</th>
<th class="Rrule Toprule" align="center">All Grades <br>(%)</th>
<th class="Rrule Toprule" align="center">Grade 3/4 <br>(%)</th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="5">Advanced Phase CML includes patients with Accelerated Phase and Blast Phase CML</td></tr>
<tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> includes the following terms: <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">upper abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="193322" conceptname="Right lower quadrant pain">lower abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="197981" conceptname="Abdominal tenderness">abdominal tenderness</span>, <span class="product-label-link" type="condition" conceptid="4091963" conceptname="Bowel spasm">gastrointestinal pain</span>, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span></dd>
<dt><a name="footnote-4" href="#footnote-reference-4">†</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> includes the following terms: <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4154924" conceptname="Macular eruption">macular rash</span>, <span class="product-label-link" type="condition" conceptid="135618" conceptname="Pruritic rash">pruritic rash</span>, generalized <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, popular <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, maculo-<span class="product-label-link" type="condition" conceptid="141094" conceptname="Lichen">papular rash</span></dd>
<dt><a name="footnote-5" href="#footnote-reference-5">‡</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span> includes the following terms: <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span></dd>
<dt><a name="footnote-6" href="#footnote-reference-6">§</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> includes the following terms: <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="4026047" conceptname="Sacral edema">localized edema</span>, face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span></dd>
<dt><a name="footnote-7" href="#footnote-reference-7">¶</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory tract infection</span> includes the following terms: <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">lower respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="4085100" conceptname="Viral upper respiratory tract infection">viral upper respiratory tract infection</span>, viral <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory tract infection</span> </dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">84</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">76</td>
<td class="Rrule" align="center">5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">46</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">47</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span><a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a>
</td>
<td class="Rrule" align="center">40</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">29</td>
<td class="Rrule" align="center">5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></td>
<td class="Rrule" align="center">40</td>
<td class="Rrule" align="center">26</td>
<td class="Rrule" align="center">42</td>
<td class="Rrule" align="center">37</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">37</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">42</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span><a name="footnote-reference-4" href="#footnote-4" class="Sup">†</a>
</td>
<td class="Rrule" align="center">34</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">35</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span><a name="footnote-reference-5" href="#footnote-5" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">26</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">20</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></td>
<td class="Rrule" align="center">23</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center">37</td>
<td class="Rrule" align="center">26</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td class="Rrule" align="center">22</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">36</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Increased <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> </td>
<td class="Rrule" align="center">20</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">20</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">18</td>
<td class="Rrule" align="center">4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
<td class="Rrule" align="center">20</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">21</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Increased <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> </td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">4</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></td>
<td class="Rrule" align="center">16</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">19</td>
<td class="Rrule" align="center">18</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span><a name="footnote-reference-6" href="#footnote-6" class="Sup">§</a>
</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span></td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory tract infection</span><a name="footnote-reference-7" href="#footnote-7" class="Sup">¶</a>
</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">19</td>
<td class="Rrule" align="center">6</td>
</tr>
</tbody>
</table>
<p>In the single-arm Phase 1/2 clinical trial, one patient (0.2%) experienced QTcF interval of greater than 500 milliseconds. Patients with uncontrolled or significant cardiovascular disease including QT interval prolongation were excluded by protocol. </p>
<p>Table 4 identifies the clinically relevant or severe Grade 3/4 laboratory test abnormalities for the Phase 1/2 CML safety population. </p>
<a name="table4"></a><table width="75%">
<caption><span>Table 4: Number (%) of Patients with Clinically Relevant or Severe Grade 3/4 Laboratory Test Abnormalities in Patients with CML in Study 1, Safety Population</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">Chronic Phase CML</th>
<th class="Rrule" align="center">Advanced Phase CML</th>
<th class="Rrule" align="center">All CP and AdvP CML</th>
</tr>
<tr>
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">N=406</th>
<th class="Rrule" align="center">N=140</th>
<th class="Rrule" align="center">N=546</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">n (%)</th>
<th class="Rrule" align="center">n (%)</th>
<th class="Rrule" align="center">n (%)</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="4"><span class="Bold">Hematology Parameters</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Platelet Count (Low) less than 50×10<span class="Sup">9</span>/L</td>
<td class="Rrule" align="center">102 (25)</td>
<td class="Rrule" align="center">80 (57)</td>
<td class="Rrule" align="center">182 (33)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Absolute Neutrophil Count less than 1×10<span class="Sup">9</span>/L</td>
<td class="Rrule" align="center">74 (18)</td>
<td class="Rrule" align="center">52 (37)</td>
<td class="Rrule" align="center">126 (23)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Hemoglobin (Low) less than 80 g/L</td>
<td class="Rrule" align="center">53 (13)</td>
<td class="Rrule" align="center">49 (35)</td>
<td class="Rrule" align="center">102 (19)</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="4"><span class="Bold">Biochemistry Parameters</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  SGPT/ALT greater than 5.0×ULN</td>
<td class="Rrule" align="center">39 (10)</td>
<td class="Rrule" align="center">8 (6)</td>
<td class="Rrule" align="center">47 (9)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>/AST greater than 5.0×ULN</td>
<td class="Rrule" align="center">17 (4)</td>
<td class="Rrule" align="center">4 (3)</td>
<td class="Rrule" align="center">21 (4)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Lipase greater than 2×ULN</td>
<td class="Rrule" align="center">33 (8)</td>
<td class="Rrule" align="center">4 (3)</td>
<td class="Rrule" align="center">37 (7)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Phosphorus (Low) less than 0.6 mmol/L</td>
<td class="Rrule" align="center">30 (7)</td>
<td class="Rrule" align="center">10 (7)</td>
<td class="Rrule" align="center">40 (7)</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left">  Total Bilirubin greater than 3.0×ULN</td>
<td class="Rrule" align="center">3 (1)</td>
<td class="Rrule" align="center">2 (1)</td>
<td class="Rrule" align="center">5 (1)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Underline">Additional Adverse Reactions from Multiple Clinical Trials</span></p>
<p>The following adverse reactions were reported in patients in clinical trials with BOSULIF (less than 10% of BOSULIF-treated patients). They represent an evaluation of the adverse reaction data from 870 patients with Ph+ <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> who received at least 1 dose of single-agent BOSULIF. These adverse reactions are presented by system organ class and are ranked by frequency. These adverse reactions are included based on clinical relevance and ranked in order of decreasing seriousness within each category. </p>
<p><span class="Underline">Blood and Lymphatic System Disorders</span>: <span class="Italics">1% and less than 10%</span> - <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span></p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span></span>: <span class="Italics">1% and less than 10%</span> - <span class="product-label-link" type="condition" conceptid="4161701" conceptname="Pericardial effusion">pericardial effusion</span>; <span class="Italics">0.1% and less than 1%</span> - <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span></p>
<p><span class="Underline">Ear and Labyrinth Disorders</span>: <span class="Italics">1% and less than 10%</span> - <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span></p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span>: <span class="Italics">1% and less than 10%</span> - <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>; <span class="Italics">0.1% and less than 1%</span> - <span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">acute pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span> (includes <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="193250" conceptname="Gastric hemorrhage">gastric hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4291649" conceptname="Upper gastrointestinal hemorrhage">upper gastrointestinal hemorrhage</span>) </p>
<p><span class="Underline">General Disorders and Administrative Site Conditions</span>: <span class="Italics">1% and less than 10%</span> - <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> (includes <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> and <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest discomfort</span>), <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></p>
<p><span class="Underline">Hepatobiliary Disorders</span>: <span class="Italics">1% and less than 10%</span> - hepatotoxicity (includes hepatotoxicity, toxic <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">cytolytic hepatitis</span>), abnormal hepatic function (includes abnormal hepatic function, <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">liver disorder</span>); <span class="Italics">0.1% and less than 1%</span> - <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span></p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span></span>: <span class="Italics">1% and less than 10%</span> - <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">drug hypersensitivity</span>; <span class="Italics">0.1% and less than 1%</span> - <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span></p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></span>: <span class="Italics">1% and less than 10%</span> - <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (includes <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="256722" conceptname="Bronchopneumonia">bronchopneumonia</span>, <span class="product-label-link" type="condition" conceptid="4133224" conceptname="Lobar pneumonia">lobar pneumonia</span>, <span class="product-label-link" type="condition" conceptid="4050869" conceptname="Atypical pneumonia">primary atypical pneumonia</span>), <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span> </p>
<p><span class="Underline">Investigations</span>: <span class="Italics">1% and less than 10%</span> - <span class="product-label-link" type="condition" conceptid="4008859" conceptname="Prolonged QT interval">electrocardiogram QT prolonged</span>, increased <span class="product-label-link" type="condition" conceptid="4294804" conceptname="Creatine kinase">blood creatine phosphokinase</span>, increased blood creatinine</p>
<p><span class="Underline">Metabolism and Nutrition Disorder</span>: <span class="Italics">1% and less than 10%</span> - <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span></p>
<p><span class="Underline">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorder</span></span>: <span class="Italics">1% and less than 10%</span> - <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span></p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span>: <span class="Italics">1% and less than 10%</span> - <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span></p>
<p><span class="Underline">Renal and Urinary Disorders</span>: <span class="Italics">1% and less than 10%</span> - <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span></p>
<p><span class="Underline">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span>: <span class="Italics">1% and less than 10%</span> - <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>; <span class="Italics">0.1% and less than 1%</span> - <span class="product-label-link" type="condition" conceptid="261600" conceptname="Acute pulmonary edema">acute pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span>, <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span></p>
<p><span class="Underline">Skin and Subcutaneous Disorders</span>: <span class="Italics">1% and less than 10%</span> - <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>; <span class="Italics">0.1% and less than 1%</span> - <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, exfoliative <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4080559" conceptname="Baboon syndrome">drug eruption</span></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Drugs That May Increase Bosutinib Plasma Concentrations</h2>
<p class="First">CYP3A or P-glycoprotein (P-gp) inhibitors: Avoid the concomitant use of strong or moderate CYP3A and/or P-gp inhibitors with BOSULIF as an increase in bosutinib plasma concentration is expected <span class="Italics">[see <a href="#S2.5">Dosage and Administration (2.5)</a>]</span>. In a dedicated cross-over drug-interaction trial in healthy volunteers (N=24), concomitant ketoconazole (strong CYP3A inhibitor) increased bosutinib C<span class="Sub">max</span> 5.2-fold and AUC 8.6-fold compared to BOSULIF alone <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Drugs That May Decrease Bosutinib Plasma Concentrations</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.1"></a><p></p>
<p class="First"><span class="Underline">CYP3A Inducers:</span> Avoid the concomitant use of strong or moderate CYP3A inducers with BOSULIF as a large reduction in exposure is expected <span class="Italics">[see <a href="#S2.6">Dosage and Administration (2.6)</a>].</span> In a dedicated cross-over drug-interaction trial in healthy volunteers (N=24), concomitant rifampin (strong CYP3A inducer) decreased bosutinib C<span class="Sub">max </span>by 86% and AUC by 94% compared to BOSULIF alone <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.2"></a><p></p>
<p class="First"><span class="Underline">Proton Pump Inhibitors:</span> In a dedicated cross-over drug-interaction trial in healthy volunteers (N=24), concomitant lansoprazole (PPI) decreased bosutinib C<span class="Sub">max</span> by 46% and AUC by 26% compared to BOSULIF alone <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>. </p>
<p>Consider using short-acting antacids or H2 blockers instead of PPIs to avoid a reduction in bosutinib exposure. Separate antacid or H2 blocker dosing and BOSULIF dosing by more than 2 hours.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Drugs That May Have Their Plasma Concentrations Altered By Bosutinib</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.1"></a><p></p>
<p class="First"><span class="Underline">Substrates of P-glycoprotein:</span> An <span class="Italics">in vitro</span> study suggests that BOSULIF may have the potential to increase the plasma concentrations of drugs that are P-gp substrates, such as digoxin <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Bold">Pregnancy Category D [see <a href="#S5.6">Warnings and Precautions (5.6)</a>]</span></p>
<p>Based on its mechanism of action and findings in animals, BOSULIF can cause fetal harm when administered to a pregnant woman. Studies in animals showed reproductive toxicities. If BOSULIF is used during pregnancy, or if the patient becomes pregnant while taking BOSULIF, the patient should be apprised of the potential hazard to the fetus. </p>
<p>Fetal exposure to bosutinib-derived radioactivity during pregnancy was demonstrated in a placental-transfer study in pregnant rats. Bosutinib was administered orally to pregnant rats during the period of organogenesis at doses of 1, 3 and 10 mg/kg/day. This study did not expose pregnant rats to enough bosutinib to fully evaluate adverse outcomes. </p>
<p>In a study conducted in rabbits, bosutinib was administered orally to pregnant animals during the period of organogenesis at doses of 3, 10 and 30 mg/kg/day. At the maternally-toxic dose of 30 mg/kg/day of bosutinib, there were fetal anomalies (fused sternebrae, and two fetuses had various visceral observations), and an approximate 6% decrease in fetal body weight. The dose of 30 mg/kg/day resulted in exposures (AUC) approximately 4 times those in humans at the 500 mg/day dose of bosutinib. </p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether bosutinib is excreted in human milk. Bosutinib and/or its metabolites were excreted in the milk of lactating rats. Radioactivity was present in the plasma of suckling offspring 24 to 48 hours after lactating rats received a single oral dose of radioactive bosutinib. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from BOSULIF, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and efficacy of BOSULIF in patients less than 18 years of age have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">In the Phase 1/2 clinical trial of BOSULIF in patients with Ph+ CML, 20% were age 65 and over, 4% were 75 and over. No overall differences in safety or effectiveness were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> </h2>
<p class="First">Treat with a dose of 200 mg daily in patients with any baseline <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. In a dedicated <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> trial, the exposure to bosutinib increased (C<span class="Sub">max</span> increased 1.5- to 2.3-fold and the AUC increased 1.9- to 2.4-fold) in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh classes A, B, and C; N=18) compared to matched healthy volunteers (N=9) <span class="Italics">[see <a href="#S2.7">Dosage and Administration (2.7)</a>, <a href="#S6">Adverse Reactions (6)</a>, and <a href="#S12.3">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.7"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </h2>
<p class="First">Reduce the BOSULIF starting dose in patients with severe (CLcr less than 30 mL/min) or moderate (CLcr 30 to 50 mL/min) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> at baseline. For patients who have declining renal function while on BOSULIF who cannot tolerate a 500 mg dose, follow dose adjustment recommendations for toxicity. In a dedicated <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> trial, compared to subjects with normal renal function, the exposure (AUC) of bosutinib increased by 60% and 35% in subjects with CLcr less than 30 mL/min and CLcr 30 to 50 mL/min, respectively, compared to subjects with normal renal function <span class="Italics">[see <a href="#S2.7">Dosing and Administration (2.7)</a> and <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>. </p>
<p>BOSULIF has not been studied in patients undergoing hemodialysis.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Experience with BOSULIF <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> in clinical studies was limited to isolated cases. There were no reports of any serious adverse events associated with the <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span>. Patients who take an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of BOSULIF should be observed and given appropriate supportive treatment.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Bosutinib is a kinase inhibitor. The chemical name for bosutinib monohydrate is 3-Quinolinecarbonitrile, 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl) propoxy]-, hydrate (1:1). Its chemical formula is C<span class="Sub">26</span>H<span class="Sub">29</span>Cl<span class="Sub">2</span>N<span class="Sub">5</span>O<span class="Sub">3</span>∙H<span class="Sub">2</span>O (monohydrate); its molecular weight is 548.46 (monohydrate), equivalent to 530.46 (anhydrous). Bosutinib monohydrate has the following chemical structure: </p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=adc84ad5-a04d-4fee-9ba8-91f7abd928e3&amp;name=bosulif-01.jpg"></div>
<p>Bosutinib monohydrate is a white to yellowish-tan powder. Bosutinib monohydrate has a pH dependent solubility across the physiological pH range. At or below pH 5, bosutinib monohydrate behaves as a highly soluble compound. Above pH 5, the solubility of bosutinib monohydrate reduces rapidly.</p>
<p>BOSULIF<span class="Sup">®</span> (bosutinib) tablets are supplied for oral administration in two strengths: a 100 mg yellow, oval, biconvex, film-coated tablet debossed with "Pfizer" on one side and "100" on the other; and a 500 mg red, oval, biconvex, film-coated tablet debossed with "Pfizer" on one side and "500" on the other. </p>
<p>Each 100 mg BOSULIF tablet contains 103.40 mg of bosutinib monohydrate, equivalent to 100 mg of bosutinib; each 500 mg BOSULIF tablet contains 516.98 mg of bosutinib monohydrate, equivalent to 500 mg of bosutinib. The following inactive ingredients are included in the tablets: microcrystalline cellulose, croscarmellose sodium, poloxamer, povidone, magnesium stearate, polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and iron oxide yellow (for 100 mg tablet) and iron oxide red (for 500 mg tablet). </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Bosutinib is a tyrosine kinase inhibitor. Bosutinib inhibits the Bcr-Abl kinase that promotes CML; it is also an inhibitor of Src-family kinases including Src, Lyn, and Hck. Bosutinib inhibited 16 of 18 imatinib-resistant forms of Bcr-Abl expressed in murine myeloid cell lines. Bosutinib did not inhibit the T315I and V299L mutant cells. In mice, treatment with bosutinib reduced the size of CML tumors relative to controls and inhibited growth of murine myeloid tumors expressing several imatinib-resistant forms of Bcr-Abl. </p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">The effect of a single dose of bosutinib 500 mg alone and with ketoconazole on the QTc interval was evaluated in a randomized, placebo- and active-controlled (moxifloxacin 400 mg) two or three-period crossover thorough QT study in 60 healthy subjects. No significant changes in placebo adjusted, baseline-corrected QTc were observed. </p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Underline">Absorption</span></p>
<p>Following administration of a single dose of BOSULIF 500 mg with food in patients with cancer, the median time-to-peak concentration (t<span class="Sub">max</span>) was 4–6 hours. Bosutinib exhibits dose proportional increases in AUC and C<span class="Sub">max</span>, over the dose range of 200 to 800 mg. After 15 daily doses of BOSULIF (500 mg) with food in patients with CML, the mean (SD) C<span class="Sub">max</span> value was 200 (12) ng/mL, and the mean (SD) AUC was 3650 (425) ng∙h/mL. When given with a high fat meal, the C<span class="Sub">max</span> and AUC of bosutinib increased 1.8- and 1.7-fold, respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Underline">Distribution</span></p>
<p>After administration of a single dose of BOSULIF 500 mg with food in patients with CML, bosutinib had a mean apparent volume of distribution ± standard deviation of 6080 ± 1230 L.</p>
<p>Bosutinib was highly bound to human plasma proteins <span class="Italics">in vitro</span> (94%) and <span class="Italics">ex vivo</span> in healthy subjects (96%), and binding was not concentration-dependent. Bosutinib is a P-gp substrate and inhibitor <span class="Italics">in vitro</span>. No studies have been conducted with other transporters. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Underline">Metabolism</span></p>
<p>Bosutinib is primarily metabolized by CYP3A4. The major circulating metabolites identified in plasma are oxydechlorinated (M2) bosutinib (19% of parent exposure) and <span class="Italics">N</span>-desmethylated (M5) bosutinib (25% of parent exposure), with bosutinib <span class="Italics">N</span>-oxide (M6) as a minor circulating metabolite. All the metabolites were deemed inactive. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Underline">Elimination</span></p>
<p>In patients with CML given single oral doses of BOSULIF 500 mg with food, the mean terminal phase elimination half-life (t<span class="Sub">1/2</span>) was 22.5 (1.7) hours, and the mean (SD) clearance (Cl/F) was 189 (48) L/h. In six healthy male subjects given a single oral dose of [<span class="Sup">14</span>C] radiolabeled bosutinib, 91.3% of the dose was recovered in feces and 3% of the dose recovered in urine. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>In a dedicated <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> trial, a single dose of BOSULIF 200 mg was administered with food to 18 volunteers with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh classes A, B, and C) and 9 matched healthy volunteers. C<span class="Sub">max</span> of bosutinib increased 2.4-fold, 2-fold, and 1.5-fold, respectively, in Child-Pugh classes A, B, and C, and bosutinib AUC increased 2.3-fold, 2-fold, and 1.9-fold, respectively <span class="Italics">[see <a href="#S2.7">Dosage and Administration (2.7)</a>, and <a href="#S8.6">Use in Specific Populations (8.6)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>In a dedicated <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> trial, a single dose of BOSULIF 200 mg was administered with food to 26 subjects with mild (CLcr: 51 to 80 mL/min), moderate (CLcr: 30 to 50 mL/min) or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CLcr less than 30 mL/min) and to 8 subjects with normal renal function. Creatinine Clearance for category classification was calculated by the Cockcroft-Gault formula. Subjects with moderate and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> had a 35% and 60% increase in AUC compared to subjects with normal renal function, respectively. Bosutinib exposure was not changed in subjects with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. The BOSULIF dose should be reduced in patients with severe (CLcr less than 30 mL/min) or moderate (CLcr between 30 to 50 mL/min) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see <a href="#S2.1">Dosage and Administration (2.1)</a> and <a href="#S8.7">Use in Specific Populations (8.7)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.7"></a><p></p>
<p class="First"><span class="Underline">Drug Interactions</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.7.1"></a><p></p>
<p class="First"><span class="Italics">CYP3A Inhibitors</span></p>
<p>In a cross-over trial of 24 healthy volunteers, a single dose of 100 mg of BOSULIF was either administered alone or in combination with five daily doses of 400 mg of ketoconazole under fasting conditions. Ketoconazole increased bosutinib C<span class="Sub">max</span> and AUC 5.2-fold and 8.6-fold, respectively <span class="Italics">[see <a href="#S2.5">Dosage and Administration (2.5)</a> and <a href="#S7.1">Drug Interactions (7.1)</a>]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.7.2"></a><p></p>
<p class="First"><span class="Italics">CYP3A Inducers</span></p>
<p>In a cross-over trial of 24 healthy volunteers, a single dose of 500 mg of BOSULIF was either administered alone or in combination with six daily doses of 600 mg of rifampin under fed conditions. Rifampin decreased bosutinib C<span class="Sub">max</span> and AUC by 86% and 94%, respectively <span class="Italics">[see <a href="#S2.5">Dosage and Administration (2.5)</a> and <a href="#S7.2">Drug Interactions (7.2)</a>]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.7.3"></a><p></p>
<p class="First"><span class="Italics">P-gp Substrates</span></p>
<p>An <span class="Italics">in vitro</span> study suggests that BOSULIF has the potential to increase the plasma concentrations of drugs that are P-gp substrates. The estimated I/IC<span class="Sub">50</span> was 0.19, when considering the C<span class="Sub">max</span> at the 500 mg dose of BOSULIF. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.7.4"></a><p></p>
<p class="First"><span class="Italics">pH Altering Medications</span></p>
<p>BOSULIF displays pH-dependent aqueous solubility, <span class="Italics">in vitro.</span> In a cross-over trial in 24 healthy volunteers, a single oral dose of 400 mg of BOSULIF was either administered alone or in combination with multiple-oral doses of 60 mg of lansoprazole under fasting conditions. Lansoprazole decreased bosutinib C<span class="Sub">max</span> and AUC by 46% and 26%, respectively. </p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">A 2-year carcinogenicity study was conducted orally in rats at bosutinib doses up to 25 mg/kg/day in males and 15 mg/kg/day in females. The exposures achieved at the high dose were approximately 1.5- to 3-fold the human exposure (based on AUC) at the bosutinib dose of 500 mg/day. The study was negative for carcinogenic findings. </p>
<p>Bosutinib was not mutagenic or clastogenic in a battery of tests, including the bacteria reverse mutation assay (Ames Test), the <span class="Italics">in vitro</span> assay using human peripheral blood <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> and the micronucleus test in orally treated male mice.</p>
<p>In a rat fertility study, drug-treated males were mated with untreated females, or untreated males were mated with drug-treated females. Females were administered the drug from pre-mating through early embryonic development. The dose of 70 mg/kg/day of bosutinib resulted in reduced fertility in males as demonstrated by 16% reduction in the number of pregnancies. There were no lesions in the male reproductive organs at this dose. This dose of 70 mg/kg/day resulted in exposure (AUC) in male rats approximately equal to that in humans at the 500 mg/day dose of bosutinib. Fertility (number of pregnancies) was not affected when female rats were treated with bosutinib. However, there were increased embryonic resorptions at greater than or equal to 10 mg/kg/day of bosutinib (40% of the human exposure), and decreased implantations and reduced number of viable embryos at 30 mg/kg/day of bosutinib (1.4 times the human exposure). </p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1"></a><p></p>
<p class="First"><span class="Underline">Imatinib-Resistant or -Intolerant Ph+ Chronic Phase (CP), Accelerated Phase (AP) and Blast Phase (BP) CML</span></p>
<p>A single-arm, Phase 1/2 open-label, multicenter trial (Study 1) was conducted to evaluate the efficacy and safety of BOSULIF 500 mg once daily in patients with imatinib-resistant or -intolerant CML with separate cohorts for chronic, accelerated, and blast phase disease previously treated with one prior TKI (imatinib) or more than one TKI (imatinib followed by dasatinib and/or nilotinib)<span class="Italics">.</span> The definition of imatinib resistance included (1) failure to achieve or maintain any hematologic improvement within four weeks; (2) failure to achieve a complete hematologic response (CHR) by 3 months, cytogenetic response by 6 months or major cytogenetic response (MCyR) by 12 months; (3) progression of disease after a previous cytogenetic or hematologic response; or (4) presence of a genetic mutation in the BCR-Abl gene associated with imatinib resistance. Imatinib intolerance was defined as inability to tolerate imatinib due to toxicity, or progression on imatinib and inability to receive a higher dose due to toxicity. The definitions of resistance and intolerance to both dasatinib and nilotinib were similar to those for imatinib. The protocol was amended to exclude patients with a known history of the T315I mutation after 396 patients were enrolled in the trial.</p>
<p>The efficacy endpoints for patients with CP CML previously treated with one prior TKI (imatinib) were the rate of attaining MCyR at week 24 and the duration of MCyR. The efficacy endpoints for patients with CP CML previously treated with both imatinib and at least 1 additional TKI were the cumulative rate of attaining MCyR by week 24 and the duration of MCyR. The efficacy endpoints for patients with previously treated AP and BP CML were confirmed complete hematologic response (CHR) and overall hematologic response (OHR).</p>
<p>The trial enrolled 546 patients with CP, AP or BP CML. Of the total patient population 73% were imatinib resistant and 27% were imatinib intolerant<span class="Italics">.</span> In this trial, 53% of patients were males, 65% were Caucasian, and 20% were 65 years old or older<span class="Italics">.</span> Of the 546 treated patients, 503 were considered evaluable for efficacy. Patients were evaluable for efficacy if they had received at least one dose of BOSULIF and had a valid baseline efficacy assessment. Among evaluable patients, there were 266 patients with CP CML previously treated with one prior TKI (imatinib), 108 patients with CP CML previously treated with both imatinib and at least 1 additional TKI, and 129 patients with advanced phase CML previously treated with at least one TKI. </p>
<p>Median duration of BOSULIF treatment was 22 months in patients with CP CML previously treated with one TKI (imatinib), 8 months in patients with CP CML previously treated with imatinib and at least 1 additional TKI, 10 months in patients with AP CML previously treated with at least imatinib, and 3 months in patients with BP CML previously treated with at least imatinib. </p>
<p>The 24 week efficacy results are present in Table 5.</p>
<a name="table5"></a><table width="70%">
<caption><span>Table 5: Efficacy Results in Patients with Ph+ CP CML with Resistance to or Intolerance to Imatinib</span></caption>
<col align="left" valign="top" width="33%">
<col align="center" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center" valign="bottom">Prior Treatment with Imatinib Only<br>(N=266 evaluable)<br>n (%)<br>at 24 Weeks</th>
<th class="Rrule" align="center">Prior Treatment with Imatinib and Dasatinib or Nilotinib<br>(N=108 evaluable)<br>n (%)<br>by 24 Weeks </th>
</tr></thead>
<tfoot><tr class="First Last"><td align="left" colspan="3">Abbreviations: CI = confidence interval, MCyR = major cytogenetic response</td></tr></tfoot>
<tbody><tr class="First Last">
<td class="Lrule Rrule" align="left">Week 24<br>  MCyR<br>  (95% CI)<br>
</td>
<td class="Rrule" align="center">
<br>90 (33.8)<br>(28.2, 39.9)</td>
<td class="Rrule" align="center">
<br>29  (26.9)<br>(18.8, 36.2)</td>
</tr></tbody>
</table>
<p>The minimum follow-up was 23 months for patients with CP CML treated with one prior TKI (imatinib) and 13 months for patients with CP CML treated with imatinib and at least one additional TKI. For the 53.4% of patients with CP CML treated with one prior TKI (imatinib) who achieved a MCyR at any time, the median duration of MCyR was not reached. Among these patients, 52.8% had a MCyR lasting at least 18 months. For the 32.4% of patients with CP CML treated with imatinib and at least one additional TKI who achieved a MCyR at any time, the median duration of MCyR was not reached. Among these patients, 51.4% had a MCyR lasting at least 9 months. Of the 374 evaluable patients with CP CML, 16 patients had confirmed disease transformation to AP or BP while on treatment with BOSULIF. </p>
<p>The 48 week efficacy results in patients with accelerated and blast phases CML previously treated with at least imatinib are summarized in Table 6. </p>
<a name="table6"></a><table width="70%">
<caption><span>Table 6: Efficacy Results in Patients with Accelerated Phase and Blast Phase CML Previously Treated with at Least Imatinib</span></caption>
<col align="left" valign="top" width="33%">
<col align="center" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">AP CML<br>(N=69 evaluable)<br>n (%)</th>
<th class="Rrule" align="center">BP CML<br>(N=60 evaluable)<br>n (%)</th>
</tr></thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="3">Abbreviations: CI = confidence interval, OHR = overall hematologic response, CHR = complete hematologic response</td></tr>
<tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">*</a></dt>
<dd>Overall hematologic response (OHR) = major hematologic response (complete hematologic response + no evidence of <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span>) or return to chronic phase (RCP). All responses were confirmed after 4 weeks. Complete hematologic response (CHR) for AP and BP CML: WBC less than or equal to institutional ULN, platelets greater than or equal to 100,000/mm<span class="Sup">3</span> and less than 450,000/mm<span class="Sup">3</span>, absolute neutrophil count (ANC) greater than or equal to 1.0×10<span class="Sup">9</span> /L, no blasts or promyelocytes in peripheral blood, less than 5% myelocytes + metamyelocytes in bone marrow, less than 20% <span class="product-label-link" type="condition" conceptid="4172647" conceptname="Basophil count">basophils</span> in peripheral blood, and no extramedullary involvement. No evidence of <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> (NEL): Meets all other criteria for CHR except may have <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (platelets greater than or equal to 20,000/mm<span class="Sup">3</span> and less than 100,000/mm<span class="Sup">3</span>) and/or <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (ANC greater than or equal to 0.5×10<span class="Sup">9</span> /L and less than 1.0×10<span class="Sup">9</span> /L). Return to chronic phase (RCP) =disappearance of features defining accelerated or blast phases but still in chronic phase.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">CHR<a name="footnote-reference-8" href="#footnote-8" class="Sup">*</a> by Week 48<br>  (95% CI)<br>
</td>
<td class="Rrule" align="center">21 (30.4)<br>19.9, 42.7)</td>
<td class="Rrule" align="center">9 (15)<br>(7.1, 26.6)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">OHR<a href="#footnote-8" class="Sup">*</a> by Week 48</td>
<td class="Rrule" align="center">38 (55.1)</td>
<td class="Rrule" align="center">17 (28.3)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  (95% CI)</td>
<td class="Rrule" align="center">(42.6, 67.1)</td>
<td class="Rrule" align="center">(17.5, 41.4)</td>
</tr>
</tbody>
</table>
<p>The CHR and OHR rates were based on a minimum follow-up of 12 months for patients with AP CML and 18 months for patients with BP CML. Of the 69 evaluable patients with AP CML, 4 patients had confirmed disease transformation to BP while on BOSULIF treatment.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S16.1"></a><a name="section-14.1"></a><p></p>
<h2>16.1 How Supplied</h2>
<p class="First">BOSULIF (bosutinib) tablets are supplied for oral administration in two strengths:  a 100 mg yellow, oval, biconvex, film-coated tablet debossed with "Pfizer" on one side and "100" on the other; and a 500 mg red, oval, biconvex, film-coated tablet debossed with "Pfizer" on one side and "500" on the other. BOSULIF (bosutinib) tablets are available in the following packaging configurations (Table 7): </p>
<a name="table7"></a><table width="100%">
<caption><span>Table 7: Tablet Presentations</span></caption>
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead>
<tr class="Botrule First"><th class="Lrule Rrule" align="center" colspan="4">BOSULIF Tablets</th></tr>
<tr class="Last">
<th class="Lrule Rrule" align="center">Package Configuration</th>
<th class="Rrule" align="center">Tablet Strength (mg)</th>
<th class="Rrule" align="center">NDC</th>
<th class="Rrule" align="center">Tablet Description</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">120 tablets per bottle</td>
<td class="Rrule" align="center">100 mg</td>
<td class="Rrule" align="center">0069-0135-01</td>
<td class="Rrule" align="left">Yellow, oval, biconvex, film-coated tablets, debossed "Pfizer" on one side and "100" on the other.</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">30 tablets per bottle</td>
<td class="Rrule" align="center">500 mg</td>
<td class="Rrule" align="center">0069-0136-01<br>
</td>
<td class="Rrule" align="left">Red, oval, biconvex, film-coated tablets, debossed "Pfizer" on one side and "500" on the other.</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="S16.2"></a><a name="section-14.2"></a><p></p>
<h2>16.2 Storage</h2>
<p class="First">Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S16.3"></a><a name="section-14.3"></a><p></p>
<h2>16.3 Handling and Disposal</h2>
<p class="First">Procedures for proper disposal of anticancer drugs should be considered. Any unused product or waste material should be disposed of in accordance with local requirements, or drug take back programs. </p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">See FDA-approved patient labeling (<a href="#PI">Patient Information</a>).</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.1"></a><p></p>
<p class="First">• <span class="Bold">Dosing and Administration </span></p>
<p>Instruct patients to take BOSULIF exactly as prescribed, not to change their dose or to stop taking BOSULIF unless they are told to do so by their doctor. If patients miss a dose beyond 12 hours, they should be advised to take the next scheduled dose at its regular time. A double dose should not be taken to make up for any missed dose. Advise patients to take BOSULIF with food. Patients should be advised: "Do not crush or cut tablet. Do not touch or handle crushed or broken tablets."</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.2"></a><p></p>
<p class="First">• <span class="Bold">Gastrointestinal Problems </span></p>
<p>Advise patients that they may experience <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, or blood in their stools with BOSULIF and to seek medical attention promptly for these symptoms.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.3"></a><p></p>
<p class="First">• <span class="Bold">Low Blood Cell Counts</span></p>
<p>Advise patients of the possibility of developing low blood cell counts and to immediately report <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, any suggestion of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, or signs or symptoms suggestive of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or easy <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.4"></a><p></p>
<p class="First">• <span class="Bold">Liver Problems </span></p>
<p>Advise patients of the possibility of developing liver function abnormalities and to immediately report <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.5"></a><p></p>
<p class="First">• <span class="Bold"><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span> </span></p>
<p>Advise patients of the possibility of developing <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> (<span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>) and to seek medical attention promptly if these symptoms arise.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.6"></a><p></p>
<p class="First">• <span class="Bold">Renal Problems</span></p>
<p>Advise patients of the possibility of developing renal problems and to immediately report frequent urination, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span> or <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.7"></a><p></p>
<p class="First">• <span class="Bold">Other Adverse Reactions </span></p>
<p>Advise patients that they may experience other adverse reactions such as <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory tract infections</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, loss of appetite, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, or <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> with BOSULIF and to seek medical attention if symptoms are significant. There is a possibility of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.8"></a><p></p>
<p class="First">• <span class="Bold">Pregnancy and Breast-feeding </span></p>
<p>Advise patients that BOSULIF can cause fetal harm when administered to a pregnant woman. Advise women of the potential hazard to the fetus and to avoid becoming pregnant. If BOSULIF is used during pregnancy, or if the patient becomes pregnant while taking BOSULIF, the patient should be apprised of the potential hazard to the fetus. Because a potential risk to the nursing infant cannot be excluded, women that are taking BOSULIF should not breast-feed or provide breast milk to infants.</p>
<p>Counsel females of reproductive potential to use effective contraceptive measures to prevent pregnancy during and for at least 30 days after completing treatment with BOSULIF. Instruct patients to contact their physicians immediately if they become pregnant during treatment. Advise patients not to take BOSULIF treatment while pregnant or breastfeeding. If a patient wishes to restart breastfeeding after treatment, advise her to discuss the appropriate timing with her physician.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.9"></a><p></p>
<p class="First">• <span class="Bold">Drug Interactions</span></p>
<p>Advise patients that BOSULIF and certain other medicines, including over the counter medications or herbal supplements (such as St. John's wort) can interact with each other and may alter the effects of BOSULIF <span class="Italics">[see <a href="#S2.5">Dosage and Administration (2.5)</a> and <a href="#S7">Drug Interactions (7)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.10"></a><p></p>
<p class="First"><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=adc84ad5-a04d-4fee-9ba8-91f7abd928e3&amp;name=bosulif-02.jpg"></p>
<p>LAB-0443-4.0</p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="PI"></a><a name="section-16"></a><p></p>
<h1>PATIENT INFORMATION</h1>
<p class="First"><span class="Bold">BOSULIF<span class="Sup">®</span> (BAH-su-lif)<br>(bosutinib)<br>tablets</span></p>
<p><span class="Bold">What is BOSULIF?</span></p>
<p>BOSULIF is a prescription medicine used to treat adults who have a certain type of <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> called Philadelphia chromosome-positive chronic  myelogenous <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> (Ph+ CML) who no longer benefit from or did not tolerate other treatment.</p>
<p>It is not known if BOSULIF is safe and effective in children less than 18 years of age.</p>
<p><span class="Bold">Who should not take BOSULIF?</span></p>
<p>Do not take BOSULIF if you are allergic to bosutinib or any of the ingredients in BOSULIF. See the end of this leaflet for a complete list of ingredients of BOSULIF.</p>
<p><span class="Bold">What should I tell my doctor before taking BOSULIF?</span></p>
<p><span class="Bold">Before you take BOSULIF, tell your doctor if you:</span></p>
<ul>
<li>have liver problems</li>
<li>have heart problems</li>
<li>have kidney problems</li>
<li>have any other medical conditions</li>
<li>are pregnant or plan to become pregnant. BOSULIF can harm your unborn baby. You should not become pregnant while taking BOSULIF. Tell your doctor right away if you become pregnant while taking BOSULIF.</li>
<li>are a woman who may become pregnant. Use effective contraception (birth control) during and for at least 30 days after completing treatment with BOSULIF. Talk to your doctor about forms of birth control.</li>
<li>are breastfeeding or plan to breastfeed. It is not known if BOSULIF passes into your breast milk or if it can harm your baby. You and your doctor should decide if you will take BOSULIF or breastfeed. You should not do both.</li>
</ul>
<p><span class="Bold">Tell your doctor about all the medicines you take, </span>including prescription medicines, over-the-counter medicines, vitamins, and herbal supplements. BOSULIF and certain other medicines can affect each other.</p>
<p><span class="Bold">Especially tell your doctor if you take:</span></p>
<ul class="Disc">
<li>
<span class="Bold">medicines that increase the amount of BOSULIF in your blood stream, such as:</span><ul class="Circle">
<li>amprenavir (Agenerase<span class="Sup">®</span>)</li>
<li>aprepitant (Emend<span class="Sup">®</span>)</li>
<li>atazanavir (Reyataz<span class="Sup">®</span>)</li>
<li>boceprevir (Victrelis<span class="Sup">®</span>)</li>
<li>ciprofloxacin (Cipro<span class="Sup">®</span>, Proquin XR<span class="Sup">®</span>)</li>
<li>clarithromycin (Biaxin<span class="Sup">®</span>, Prevpac<span class="Sup">®</span>)</li>
<li>conivaptan (Vaprisol<span class="Sup">®</span>)</li>
<li>crizotinib (Xalkori<span class="Sup">®</span>)</li>
<li>darunavir (Prezista<span class="Sup">®</span>)</li>
<li>digoxin (Lanoxin<span class="Sup">®</span>)</li>
<li>diltiazem (Cardizem<span class="Sup">®</span>, Dilacor XR<span class="Sup">®</span>, Tiazac<span class="Sup">®</span>)</li>
<li>erythromycin (Ery-tab<span class="Sup">®</span>)</li>
<li>fluconazole (Diflucan<span class="Sup">®</span>)</li>
<li>fosamprenavir (Lexiva<span class="Sup">®</span>) </li>
<li>imatinib (Gleevec<span class="Sup">®</span>)</li>
<li>indinavir (Crixivan<span class="Sup">®</span>)</li>
<li>itraconazole (Onmel<span class="Sup">®</span>, Sporanox<span class="Sup">®</span>)</li>
<li>ketoconazole (Nizoral<span class="Sup">®</span>)</li>
<li>nefazodone (Serzone<span class="Sup">®</span>)</li>
<li>nelfinavir (Viracept<span class="Sup">®</span>)</li>
<li>posaconazole (Noxafil<span class="Sup">®</span>)</li>
<li>ritonavir (Kaletra<span class="Sup">®</span>,  Norvir<span class="Sup">®</span>)</li>
<li>saquinavir (Invirase<span class="Sup">®</span>, Fortovase<span class="Sup">®</span>)</li>
<li>telaprevir (Incivek<span class="Sup">®</span>)</li>
<li>telithromycin (Ketek<span class="Sup">®</span>) </li>
<li>verapamil (Calan<span class="Sup">®</span>, Covera-HS<span class="Sup">®</span>, Tarka<span class="Sup">®</span>, Verelan PM<span class="Sup">®</span>)</li>
<li>voriconazole (Vfend<span class="Sup">®</span>)</li>
</ul>
</li>
<li>
<span class="Bold">medicines that decrease the amount of BOSULIF in your blood stream, such as:</span><ul>
<li>bosentan (Tracleer<span class="Sup">®</span>)</li>
<li>carbamazepine (Carbatrol<span class="Sup">®</span>, Equetro<span class="Sup">®</span>, Tegretol<span class="Sup">®</span>)</li>
<li>efavirenz (Sustiva<span class="Sup">®</span>)</li>
<li>etravirine (Intelence<span class="Sup">®</span>)</li>
<li>modafinil (Provigil<span class="Sup">®</span>)</li>
<li>nafcillin (Unipen<span class="Sup">®</span>, Nallpen<span class="Sup">®</span>)</li>
<li>phenobarbital (Solfoton<span class="Sup">®</span>)</li>
<li>phenytoin (Dilantin<span class="Sup">®</span>)</li>
<li>rifabutin (Mycobutin<span class="Sup">®</span>)</li>
<li>rifampin (Rifamate<span class="Sup">®</span>, Rifater<span class="Sup">®</span>, Rifadin<span class="Sup">®</span>)</li>
<li>St. John's wort</li>
</ul>
</li>
</ul>
<p><span class="Bold">BOSULIF is best absorbed from your stomach into your blood stream in the presence of stomach acid. You should avoid taking BOSULIF with medicines that reduce stomach acid, such as:</span></p>
<ul class="Circle">
<li>esomeprazole (Nexium<span class="Sup">®</span>), esomeprazole strontium</li>
<li>dexlansoprazole (Dexilant<span class="Sup">®</span>)</li>
<li>lansoprazole (Prevacid<span class="Sup">®</span>)</li>
<li>omeprazole (Prilosec<span class="Sup">®</span>, Vimovo<span class="Sup">®</span>, Zegerid<span class="Sup">®</span>)</li>
<li>pantoprazole sodium (Protonix<span class="Sup">®</span>)</li>
<li>rabeprazole (AcipHex<span class="Sup">®</span>)</li>
</ul>
<p><span class="Bold">Medicines that neutralize stomach acid, such as:</span> cimetidine (Tagamet<span class="Sup">®</span>), famotidine (Pepcid<span class="Sup">®</span>), ranitidine (Zantac<span class="Sup">®</span>), aluminum hydroxide/magnesium hydroxide (Maalox<span class="Sup">®</span>), calcium carbonate (Tums<span class="Sup">®</span>), or calcium carbonate and magnesia (Rolaids<span class="Sup">®</span>) may be taken up to 2 hours before or 2 hours after BOSULIF.</p>
<p>Know the medicines you take. Keep a list of your medicines and show it to your doctor and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take BOSULIF?</span></p>
<ul class="Disc">
<li>Take BOSULIF exactly as prescribed by your doctor.</li>
<li>Do not change your dose or stop taking BOSULIF without first talking with your doctor.</li>
<li>Take BOSULIF with food.</li>
<li>Swallow BOSULIF tablets whole. Do not crush or cut BOSULIF tablets. Do not touch or handle crushed or broken BOSULIF tablets.</li>
<li>You should avoid grapefruit, grapefruit juice, and supplements that contain grapefruit extract during treatment with BOSULIF. Grapefruit products increase the amount of BOSULIF in your body.</li>
<li>Your doctor may change your dose of BOSULIF or tell you to stop taking BOSULIF depending on how you respond to treatment.</li>
<li>If you miss a dose of BOSULIF, take it as soon as you remember. If you miss a dose by more than 12 hours, skip that dose and take your next dose at your regular time. Do not take two doses at the same time.</li>
<li>If you take too much BOSULIF, call your doctor or go to the nearest hospital emergency room right away.</li>
</ul>
<p><span class="Bold">What are the possible side effects of BOSULIF?</span></p>
<p>BOSULIF may cause serious side effects, including:</p>
<ul class="Disc">
<li>
<span class="Bold">Stomach problems.</span> BOSULIF may cause stomach (abdomen) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Tell your doctor about any stomach problems.</li>
<li>
<span class="Bold">Low blood cell counts</span>. BOSULIF may cause low platelet counts (<span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>), low red blood cell counts (<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>) and low white blood cell counts (<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>). Your doctor should do blood tests to check your blood cell counts regularly during your treatment with BOSULIF. Call your doctor right away if you have unexpected <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, blood in your urine or stools, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, or any signs of an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</li>
<li>
<span class="Bold">Liver problems.</span> BOSULIF may cause liver problems. Your doctor should do blood tests to check your liver function regularly during your treatment with BOSULIF. Call your doctor right away if your skin or the white part of your eyes turns yellow (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>) or you have dark "tea color" urine.</li>
<li>
<span class="Bold">Your body may hold too much fluid (<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>). </span>Fluid may build up in the lining of your lungs, the sac around your heart, or your stomach cavity. Call your doctor right away if you get any of the following symptoms during your treatment with BOSULIF:<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> and <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span></li>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> in your hands, ankles, or feet</li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> all over your body</li>
<li><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span></li>
</ul>
</li>
<li>
<span class="Bold">Kidney problems.</span> BOSULIF may cause kidney problems. Your doctor should do tests to check your kidney function when you start treatment with BOSULIF and during your treatment. Call your doctor right away if you get any of the following symptoms during your treatment with BOSULIF: 								<ul class="Disc">
<li>you urinate more often than normal</li>
<li>you urinate less often than normal</li>
<li>you make a much larger amount of urine than normal</li>
<li>you make a much smaller amount of urine than normal</li>
</ul>
</li>
</ul>
<p><span class="Bold">Other common side effects of BOSULIF include:</span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></li>
</ul>
<p><span class="Bold">Tell your doctor right away if you get <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory tract infections</span>, loss of appetite, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>, or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> while taking BOSULIF. These may be symptoms of a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>. </span></p>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all of the possible side effects of BOSULIF. For more information, ask your doctor or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How do I store BOSULIF?</span></p>
<ul>
<li>Store BOSULIF between 68°F to 77°F (20°C to 25°C).</li>
<li>Ask your doctor or pharmacist about the right way to throw away outdated or unused BOSULIF.</li>
</ul>
<p><span class="Bold">Keep BOSULIF and all medicines out of the reach of children. </span></p>
<p><span class="Bold">General information about BOSULIF.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use BOSULIF for a condition for which it is not prescribed. Do not give BOSULIF to other people even if they have the same symptoms you have. It may harm them.</p>
<p>This Patient Information leaflet summarizes the most important information about BOSULIF. If you would like more information, talk with your doctor. You may ask your doctor or pharmacist for information about BOSULIF that is written for healthcare professionals.</p>
<p>For more information, go to<span class="Bold"> www.Bosulif.com </span>or<span class="Bold"> www.pfizermedicalinformation.com </span>or call  <span class="Bold">1-800-438-1985.</span></p>
<p><span class="Bold">What are the ingredients in BOSULIF?</span></p>
<p><span class="Bold">Active ingredient: </span>bosutinib.</p>
<p><span class="Bold">Inactive ingredients:</span> microcrystalline cellulose, croscarmellose sodium, poloxamer, povidone, magnesium stearate, polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and iron oxide yellow (for 100 mg tablet) and iron oxide red (for 500 mg tablet).</p>
<p>This Patient Information has been approved by the U.S. Food and Drug Administration.</p>
<p><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=adc84ad5-a04d-4fee-9ba8-91f7abd928e3&amp;name=bosulif-02.jpg"></p>
<p>LAB-0639-4.0</p>
<p>November 2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 100 mg Bottle Label</span></p>
<p><span class="Bold Italics">Pfizer</span></p>
<p>NDC 0069-0135-01</p>
<p><span class="Bold">Bosulif<span class="Sup">®</span><br>(bosutinib) tablets</span></p>
<p><span class="Bold">100 mg*</span></p>
<p>Do not crush or cut tablet<br>For Oncology Use Only</p>
<p>120 Tablets</p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 100 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=adc84ad5-a04d-4fee-9ba8-91f7abd928e3&amp;name=bosulif-03.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 500 mg Bottle Label</span></p>
<p><span class="Bold Italics">Pfizer</span></p>
<p>NDC 0069-0136-01</p>
<p><span class="Bold">Bosulif<span class="Sup">®</span><br>(bosutinib) tablets</span></p>
<p><span class="Bold">500 mg*</span></p>
<p>Do not crush or cut tablet<br>For Oncology Use Only</p>
<p>30 Tablets</p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 500 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=adc84ad5-a04d-4fee-9ba8-91f7abd928e3&amp;name=bosulif-04.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BOSULIF 		
					</strong><br><span class="contentTableReg">bosutinib monohydrate tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0069-0135</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>BOSUTINIB MONOHYDRATE</strong> (BOSUTINIB) </td>
<td class="formItem">BOSUTINIB MONOHYDRATE</td>
<td class="formItem">100 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE K25</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3350</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLOXAMER 188</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Pfizer;100</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0069-0135-01</td>
<td class="formItem">120  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA203341</td>
<td class="formItem">09/04/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BOSULIF 		
					</strong><br><span class="contentTableReg">bosutinib monohydrate tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0069-0136</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>BOSUTINIB MONOHYDRATE</strong> (BOSUTINIB) </td>
<td class="formItem">BOSUTINIB MONOHYDRATE</td>
<td class="formItem">500 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE K25</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3350</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLOXAMER 188</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">RED</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Pfizer;500</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0069-0136-01</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA203341</td>
<td class="formItem">09/04/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Pfizer Laboratories Div Pfizer Inc
							(134489525)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pfizer Manufacturing Deutschland GmbH (Betriebsstätte Freiburg)</td>
<td class="formItem"></td>
<td class="formItem">341970073</td>
<td class="formItem">PACK(0069-0135), LABEL(0069-0135), ANALYSIS(0069-0135), MANUFACTURE(0069-0135)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Excella GmbH</td>
<td class="formItem"></td>
<td class="formItem">329809800</td>
<td class="formItem">MANUFACTURE(0069-0135), ANALYSIS(0069-0135)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Esteve Quimica, SA</td>
<td class="formItem"></td>
<td class="formItem">633485529</td>
<td class="formItem">API MANUFACTURE(0069-0136, 0069-0135)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>96ef2aac-7c4f-4e9d-9a0e-414f7385682b</div>
<div>Set id: adc84ad5-a04d-4fee-9ba8-91f7abd928e3</div>
<div>Version: 6</div>
<div>Effective Time: 20141204</div>
</div>
</div> <div class="DistributorName">Pfizer Laboratories Div Pfizer Inc</div></p>
</body></html>
